NewYork-Presbyterian Logo
 
ADVANCES IN RHEUMATOLOGY  
Affiliated with Columbia University College of Physicians and Surgeons and Weill Cornell Medical College  
 

NOVEMBER/DECEMBER 2014

Home

Download Newsletter

Addressing the Ongoing Challenges of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: Understanding and Managing Renal Involvement



National Rheumatology Badge



CONTINUING
MEDICAL EDUCATION

For all upcoming education events through NewYork-Presbyterian Hospital, see calendar of events.


 

Systemic Lupus Erythematosus:
Understanding and Managing Renal Involvement

  Dr. Kyriakos A. Kirou

Twice a year on a Friday, Kyriakos A. Kirou, MD, DSc, Clinical Co-Director of the Mary Kirkland Center for Lupus Care and Director of the Lupus Nephritis Program at Hospital for Special Surgery, and other HSS rheumatologists are joined by nephrologists and a renal pathologist from NewYork-Presbyterian/Weill Cornell Medical Center for the express purpose of an in-depth discussion of the care of challenging cases of patients with lupus nephritis, their optimal therapy, and outcomes. Discussion of lupus nephritis cases continues, less formally, every Friday, and literally at any time there is a need to do so, especially when rheumatology fellows need advice with their cases.

"We established the Lupus Nephritis Program to allow us to focus specifically on this disease because it's complicated and it requires a multidisciplinary approach," says Dr. Kirou. "Our goal is to provide the best possible care for our lupus nephritis patients by using the exceptional resources available to us at Hospital for Special Surgery and NewYork-Presbyterian/Weill Cornell. Our approach includes the close collaboration of rheumatologists, nephrologists, a kidney pathologist, our nurse practitioner, and infusion room nurses."

In addition to many other complications of lupus – including cardiovascular, pulmonary, musculoskeletal, gastrointestinal, and neuro-psychiatric – lupus nephritis is a prominent feature of the disease. "Approximately half of lupus patients develop lupus nephritis, usually early in the course of SLE," says Dr. Kirou, "and approximately 10 to 20 percent of those will progress to dialysis or transplantation.

"When the kidney is affected, a very common finding is swelling of the feet," explains Dr. Kirou. "Blood pressure can be high, which can cause headaches. And in a minority of patients, the urine becomes dark signifying the presence of blood, or foamy because protein is present. These are all clues for the rheumatologist to consider that the patient may have nephritis."

Dr. Kirou notes that as the disease becomes more active, the patient may have a high ANA titer and a positive anti-double-stranded DNA test. "The levels of complement proteins C3 and C4 are often low, especially in lupus nephritis, reflecting the activation of the immune system," explains Dr. Kirou. "Below 90 mg/dl for C3 and below 16 mg/dl for the C4 are considered low, but the lower they become, the more likely they are to be indicative of severe disease."

  (From left) Surya V. Seshan, MD, kidney pathologist, Miriam Chung, MD, and James M. Chevalier, MD,
nephrologists, and Kyriakos A. Kirou, MD, DSc, and Doruk Erkan, MD, rheumatologists, during a weekly
conference of the Lupus Nephritis Program

While symptom presentation and laboratory tests can indicate a diagnosis of lupus nephritis, Dr. Kirou notes that renal ultrasound may be recommended to first rule out other causes of kidney disease. A kidney biopsy is then typically performed on all patients with clinical evidence of previously untreated active lupus nephritis.

"The biopsy will allow us to determine the degree of activity, the degree of inflammation in the kidney, and the degree of scarring," says Dr. Kirou. "If a lot of scarring is present but not much disease activity, then we generally do not recommend immunosuppressant medications since there's little or no room for improvement. These patients will likely go on to need hemodialysis or kidney transplant. Patients who are active on the biopsy will need aggressive therapy. The biopsy also helps us decide what therapy to administer. Our renal pathologist, Dr. Surya Seshan, reads the biopsies of all of our patients and helps us arrive at the right diagnosis and then the right treatment approach for each patient."

Classifying and Treating Lupus Nephritis
A kidney biopsy also enables the lupus nephritis to be classified according to the International Society of Nephrology/Renal Pathology Society 2003 Classification of Lupus Nephritis and evaluated in terms of its activity and chronicity. The biopsy can also help exclude other causes for the renal disease such as acute tubular necrosis due to medications or hypovolemia.

"Class I represents very minor involvement of the kidneys and is not significant clinically. Class II also indicates a very mild degree of disease, with some inflammation present but not enough to trigger therapy," explains Dr. Kirou. "The disease becomes more serious with Class III and Class IV, representing the proliferation of cells within the kidney or other cells coming from blood in the kidney, which will eventually cause trouble with scarring and kidney function."

Class V may exist by itself or in association with Classes III and IV and is different than those. "With Class V, lupus nephritis is a membranous disease," says Dr. Kirou. "So now the problem is in the basement membrane where the glomerular capillaries – small blood vessels where blood filtration to form the urine takes place – are attached. This Class V lupus nephritis, or membranous nephritis, can be mild or more severe depending on the amount of protein leaking into the urine. Classes III, IV, and V often require aggressive treatment. Most doctors will use steroids or similar compounds because they work quickly. The treatment may begin with a high dosage administered intravenously for one to three days just to get a head start on attacking the inflammation. This would be followed by an oral regimen of about 40 to
60 mg of prednisone per day.

kidney biopsy image
  Kidney biopsy from a patient with Class IV lupus nephritis showing a glomerulus with narrowing/ closing of the capillaries from an abnormal increase of cells within those vessels. (Courtesy of Dr. Surya V. Seshan, Professor of Clinical Pathology and Laboratory Medicine at Weill Cornell Medical College)

"At the same time we know that the prednisone doesn't have a long-lasting effect so we will start an induction regimen with other agents to bring the disease under control," says
Dr. Kirou. "These would be classically either cyclophosphamide or mycophenolate mofetil. After we achieve some control, hopefully the disease will respond and we will start to see reduced swelling and a decrease in proteinuria and blood in the urine, as well as an improvement in blood pressure. When we reach that stage, we want to maintain it because if we don't, the disease will come back. It's a relapsing disease. So we will want to give a maintenance therapy for at least two years or so."

Looking Ahead
Dr. Kirou recommends that in the immediate future "physicians should be more sensitized to treating lupus nephritis very aggressively and very early on. "Time is kidney," says Dr. Kirou. "It's important to act quickly and effectively, especially to prevent scarring, which is irreversible. The more attacks there are on the kidney, the more likely the patient will need dialysis."

The work of Dr. Kirou and his colleagues at HSS and NewYork-Presbyterian extends to collaborations with rheumatologists and nephrologists with an interest in lupus nephritis across the country and around the world through organizations such as the Lupus Nephritis Trials Network. The mission of this international organization of clinicians and scientists is to foster collaborations that include clinical trials designed to prevent chronic kidney disease and end-stage renal failure in patients with lupus; develop guidelines for assessing and treating patients with lupus nephritis; and pursue investigations on a wide variety of therapeutic agents, treatment methodologies, and biomarkers of disease.

Dr. Kirou is also an investigator in the ALLURE study, a Phase III randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of abatacept or placebo in combination with mycophenolate mofetil and corticosteroids in subjects with active Class III or IV lupus nephritis. The study is expected to enroll approximately 400 patients in 120 sites worldwide.

 
 

Reference Articles
Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA. A surge in anti-dsDNA titer predicts a severe lupus flare within six months. Lupus. 2014 Mar;23(3):293-98.

Kyriakos A. Kirou, MD, and Michael D. Lockshin, MD. Systemic Lupus Erythematosus. ACP Medicine. Decker Intellectual Properties Inc. 2013.

For More Information
Dr. Kyriakos A. Kirou • kirouk@hss.edu